Publication

Article

Oncology Treatment Pathways®
November 2022

Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies

Download Issue PDF
Articles in this issue
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Novel Targeted Immunotherapies in Multiple Myeloma, With a Focus on Bispecific Antibodies
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Marc Machaalani, MD
Related Content
Maurie Markman, MD, of City of Hope
October 30th 2024

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
November 18th 2021

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.
October 28th 2024

RMC-9805 Triggers Tumor Regressions in KRAS G12D–Mutant Pancreatic Cancer

Gordan on Growing the Infrastructure for In-House Genomic Testing
October 14th 2021

Gordan on Growing the Infrastructure for In-House Genomic Testing

APR-1051 in Advanced, Mutated Solid Tumors | Image Credit: © tonstock - stock.adobe.com
October 25th 2024

The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors

FDA
October 22nd 2024

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer